Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The 'GISCAD-alternating schedule' study findings

European Journal of Cancer

Volumn 45, Issue 1, 2009, Pages 65-73

  Mandalà, Mario ^a   Barni, Sandro ^b   Floriani, Irene ^c   Isa, Luciano ^d   Fornarini, Giuseppe ^e   Marangolo, Maurizio ^f   Mosconi, Stefania ^a   Corsi, Domenico ^g   Rulli, Eliana ^c   Frontini, Luciano ^h   Cortesi, Enrico ⁱ   Zaniboni, Alberto ^j   Aglietta, Massimo ^k   Labianca, Roberto ^a  

^a OSPEDALI RIUNITI   (Italy)

^b Treviglio Hospital   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d Ospedale Serbelloni   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h SAN GERARDO HOSPITAL   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j Fondazione Poliambulanza   (Italy)

^k CANDIOLO CANCER INSTITUTE   (Italy)

more..

Author keywords

Chemotherapy; Colorectal cancer; Venous thrombosis

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; HEPARIN; IRINOTECAN; LOW MOLECULAR WEIGHT HEPARIN; OXALIPLATIN; RALTITREXED;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; FEMALE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; VENOUS THROMBOEMBOLISM;

EID: 57749097351     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.09.005     Document Type: Article

References (38)

1. Cohen A.T., Tapson V.F., Bergmann J.F., et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 371 (2008) 387-394
2. Otten H.M., Mathijssen J., ten Cate H., et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy, an underestimated phenomenon. Arch Intern Med 164 (2004) 190-194
3. Labianca R, Floriani I, Isa L, et al. Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): a randomized "GISCAD" trial. Proceedings ASCO; 2006 [abstract 3505].
4. Chew H.K., Wun T., Harvey D., Zhou H., and White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006) 458-464
5. Feliu J., Castañón C., Salud A., Mel J.R., et al. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer. Brit J Cancer 93 (2005) 1230-1235
6. Van Cutsem E., Dirix L., Van Laethem J.L., et al. Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. Brit J Cancer 92 (2005) 1055-1062
7. Van Cutsem E., Hoff P.M., Harper P., et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Brit J Cancer 90 (2004) 1190-1197
8. Bajetta E., Di Bartolomeo M., Buzzoni R., et al. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. Brit J Cancer 96 (2007) 439-444
9. Souglakos J., Androulakis N., Syrigos K., et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Brit J Cancer (2006) 798-805
10. Martoni A.A., Pinto C., Di Fabio F., et al. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer 42 (2006) 3161-3168
11. Garufi C., Vanni B., Aschelter A.M., et al. Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. Eur J Cancer 42 (2006) 608-616
12. Nogué M., Salud A., Batiste-Alentorn E., et al. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer 41 (2005) 2241-2249
13. Hospers G.A.P., Schaapveld M., Nortier J.W.R., et al. Randomised phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Ann Oncol 17 (2006) 443-449
14. Goldberg R.M., Sargent D.J., Morton R.F., et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006) 3347-3353
15. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005) 4866-4875
16. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
17. Köhne C.H., van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 23 (2005) 4856-4865
18. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25 (2007) 4779-4786
19. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25 (2007) 1670-1676
20. Goldberg R.M., Sargent D.J., Morton R.F., et al. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 24 (2006) 3347-3353
21. Bécouarn Y., Senesse P., Thézenas S., et al. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Ann Oncol 18 (2007) 2000-2005
22. Comella P., Massidda B., Filippelli G., et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Ann Oncol 16 (2005) 878-886
23. Kalofonos H.P., Aravantinos G., Kosmidis P., et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 16 (2005) 869-877
24. Delaunoit T., Goldberg R.M., Sargent D.J., et al. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 101 (2004) 2170-2176
25. Koopman M., Antonini N.F., Douma J., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 370 (2007) 135-142
26. Seymour M.T., Maughan T.S., Ledermann J.A., et al., FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370 (2007) 143-152
27. Schoemaker N.E., Kuppens I.E., Moiseyenko V., et al. Randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer. Brit J Cancer 91 (2004) 1434-1441
28. Porschen R., Arkenau H.T., Kubicka S., et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin oncol 25 (2007) 4217-4223
29. Giacchetti S., Bjarnason G., Garufi C., et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24 (2006) 3562-3569
30. Ashley A.C., Sargent D.J., Alberts S.R., et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. Cancer 110 (2007) 670-677
31. Díaz-Rubio E., Tabernero J., Gómez-España A., et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25 (2007) 4224-4230
32. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 20 (2006) 394-400
33. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med 343 (2000) 905-914
34. Khorana A.A., Francis C.W., Culakova E., et al. Risk factors for chemotherapy associated venous thromboembolism in a prospective observational study. Cancer 104 (2005) 2822-2829
35. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25 (2007) 5490-5505
36. Mandala M., Falanga A., Piccioli A., et al., Working Group AIOM. Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59 (2006) 194-204
37. Alcalay A., Wun T., Khatri V., et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol 24 (2006) 1112-1118
38. Levine M.N., Gent M., Hirsh J., et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. New Engl J Med 318 (1988) 404-407